BioVentrix® Closes $48.5 Million Series A Financing
Financing led by Andera Partners including Cormorant Asset Management, Taglich [...]
New Study Demonstrates Accurate Measurement of Left Ventricular Function Following Treatment with BioVentrix Revivent TC® Therapy
Inward Displacement Approach Assesses HFrEF Patients for Left Ventricular Device [...]
BioVentrix Names Dr. Ori Ben-Yehuda as Chief Medical Officer
Brings Extensive Clinical Trial and Patient Care Experience to Senior [...]
FDA Agrees to Expanded Access Program for the BioVentrix Revivent TC® System for the Treatment of Ischemic Heart Failure
Treatment IDE Will Provide Opportunity to Treat Additional Patients in [...]
BioVentrix Expands Heart Failure Treatment Portfolio with Acquisition of MateraCor, Inc.
Revolutionary Heart Failure Therapy Company Also Adds New Executive and [...]
BioVentrix Announces Raymond W. Cohen as Chairman of the Board and Newly Appointed Accredited Public Company Directors, Rinda K. Sama and Andrew G. Hinson to its Board of Directors
SAN RAMON, Calif. – July 21, 2021 – BioVentrix, Inc., [...]
BioVentrix Names Jim Dillon President and CEO
Proven Leader Will Take Revolutionary Heart Failure Therapy Company to [...]
Kardio-Tech-Firma aus Kalifornien gründet Deutschland-Niederlassung und macht so innovative Herztherapie breiter verfügbar
San Ramon, Kalifornien, und Hilden bei Düsseldorf, 19. Februar 2021„Bringing [...]
BioVentrix Receives 2021 NUB Status 1 Reimbursement Renewal in Germany for the Revivent TC™ TransCatheter Ventricular Enhancement System
SAN RAMON, Calif. – February 8, 2021 - BioVentrix, Inc., [...]
BioVentrix Announces Jerry Estep, MD, as Co-Principal Investigator for ALIVE Pivotal Trial Studying a Transcatheter Device for Heart Failure
SAN RAMON, Calif. – January 6, 2021 – BioVentrix, Inc., [...]
